Pharmacokinetics and Pharmacodynamics with Extended Dosing of CC-486 in Patients with Hematologic Malignancies
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Pharmacokinetics and Pharmacodynamics with Extended Dosing of CC-486 in Patients with Hematologic Malignancies
Authors
Keywords
-
Journal
PLoS One
Volume 10, Issue 8, Pages e0135520
Publisher
Public Library of Science (PLoS)
Online
2015-08-22
DOI
10.1371/journal.pone.0135520
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Immune regulation by low doses of the DNA methyltransferase inhibitor 5-azacitidine in common human epithelial cancers
- (2015) Huili Li et al. Oncotarget
- Gender, Cytidine Deaminase, and 5-Aza/Decitabine--Response
- (2013) R. Z. Mahfouz et al. CLINICAL CANCER RESEARCH
- Human cytidine deaminase: A biochemical characterization of its naturally occurring variants
- (2013) Daniela Micozzi et al. INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES
- Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents
- (2013) H Yang et al. LEUKEMIA
- RNA-dependent inhibition of ribonucleotide reductase is a major pathway for 5-azacytidine activity in acute myeloid leukemia
- (2012) J. Aimiuwu et al. BLOOD
- Azacitidine differentially affects CD4pos T-cell polarization in vitro and in vivo in high risk myelodysplastic syndromes
- (2012) Hetty J. Bontkes et al. LEUKEMIA RESEARCH
- Continued azacitidine therapy beyond time of first response improves quality of response in patients with higher-risk myelodysplastic syndromes
- (2011) Lewis R. Silverman et al. CANCER
- Phase I Study of Oral Azacitidine in Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, and Acute Myeloid Leukemia
- (2011) Guillermo Garcia-Manero et al. JOURNAL OF CLINICAL ONCOLOGY
- Transcriptionally repressed genes become aberrantly methylated and distinguish tumors of different lineages in breast cancer
- (2011) D. Sproul et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- A Comparison of Azacitidine and Decitabine Activities in Acute Myeloid Leukemia Cell Lines
- (2010) Paul W. Hollenbach et al. PLoS One
- Ontology-Based Meta-Analysis of Global Collections of High-Throughput Public Data
- (2010) Ilya Kupershmidt et al. PLoS One
- Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies
- (2009) T. E. Fandy et al. BLOOD
- MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation
- (2009) M. E. Figueroa et al. BLOOD
- Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study
- (2009) Pierre Fenaux et al. LANCET ONCOLOGY
- The DNA methyltransferase inhibitors azacitidine, decitabine and zebularine exert differential effects on cancer gene expression in acute myeloid leukemia cells
- (2009) C Flotho et al. LEUKEMIA
- Azacytidine causes complex DNA methylation responses in myeloid leukemia
- (2008) C. Stresemann et al. MOLECULAR CANCER THERAPEUTICS
- Epigenetics in Cancer
- (2008) Manel Esteller NEW ENGLAND JOURNAL OF MEDICINE
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started